Cardiovascular collaboration
Cryptome Pharmaceuticals has signed a memorandum of understanding with the University of Queensland's Institute for Molecular Biosciences (IMB) to collaborate on the identification of potential therapeutics for cardiovascular disease.
The IMB will provide Cryptome with high value compound libraries, which Cryptome will screen for potential activity using its proprietary Cryptomics platform technology. The Cryptomics drug discovery platform is based on finding small protein fragments with previously undiscovered therapeutic activities. These fragments are generated, screened and identified using the Cryptomics systematic high-throughput approach.
Illumina appoints Susan Martin as General Manager, ANZ
Most recently, Martin served as Managing Director, Australia and New Zealand at Johnson &...
Monash University signs MOU with TGA Academic Outreach Program
The program fosters collaboration across research, knowledge exchange and education to support...
Report: Economic value of NATA accreditation estimated at $488–712m annually
A UTS report has explored the economic and social value of National Association of Testing...
